Related Experiment Videos

[Diagnostic value of lipids and apolipoproteins for assessment of atherogenic risk]

W Herrmann1, S Hanf, C Schütz

  • 1Bezirkskrankenhauses Meiningen, Zentralklinik für Herz- Lungenkrankheiten, Bad Berka.

Zeitschrift Fur Die Gesamte Innere Medizin Und Ihre Grenzgebiete
|February 15, 1988
PubMed

Insights

Apolipoprotein A-I, HDL3, and HDL cholesterol levels are key indicators for identifying coronary artery disease. The total/HDL cholesterol ratio effectively assesses disease severity in male patients.

Area of Science:

  • Cardiovascular Medicine
  • Clinical Chemistry
  • Lipid Metabolism

Context:

  • Coronary artery disease (CAD) is a significant health concern in male populations.
  • Lipoprotein patterns play a crucial role in the development and progression of atherosclerosis.
  • Accurate diagnostic markers are essential for early detection and risk stratification of CAD.

Purpose:

  • To investigate the diagnostic significance of various lipoprotein parameters in differentiating male patients with coronary artery disease from healthy individuals.
  • To evaluate the efficacy of different lipoprotein markers in assessing the severity of coronary artery disease.
  • To explore the influence of beta-receptor blocker medication on lipid profiles.

Summary:

  • A study analyzed lipoprotein patterns in 242 male patients with varying degrees of coronary artery disease and 68 healthy controls.
  • Apolipoprotein A-I (Apo A-I), HDL3 cholesterol, and HDL cholesterol demonstrated the highest diagnostic efficiency in distinguishing CAD patients (0.81, 0.76, 0.72 respectively).
  • The total cholesterol to HDL cholesterol ratio proved most effective (0.67 efficiency) for assessing the severity of coronary vessel changes. Beta-receptor blocker use was associated with increased triglycerides and pre-beta-cholesterol.

Impact:

  • Identifies specific lipoprotein markers (Apo A-I, HDL3, HDL cholesterol) with high diagnostic value for coronary artery disease.
  • Provides a reliable ratio (total/HDL cholesterol) for quantifying CAD severity, aiding clinical decision-making.
  • Highlights potential confounding effects of medications like beta-receptor blockers on lipid profiles, important for accurate interpretation.

Related Concept Videos